AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34531250 — intervention group
Group type: EXPERIMENTAL
Intervention: CD33-directed chimeric antigen receptor T cell immunotherapy (CD33CARTs) with CD28 costimulatory domain
Number of subjects: 0
Study 34531250 — intervention group
Group type: COMPARATOR
Intervention: CD33-directed chimeric antigen receptor T cell immunotherapy (CD33CARTs) with 4-1BB costimulatory domain
Number of subjects: 0
Study 34531250 — intervention group
Group type: COMPARATOR
Intervention: Gemtuzumab-based CD33CARTs
Number of subjects: 0
Study 34531264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent tracer cetuximab-800CW
Number of subjects: 0
Study 34531279 — intervention group
Group type: COMPARATOR
Intervention: Low dose potassium treatment
Number of subjects: 19
Study 34531279 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose potassium treatment
Number of subjects: 19
Study 34531443 — intervention group
Group type: EXPERIMENTAL
Intervention: Collar Therapy Indicator (COTI) for monitoring radioactive iodine uptake
Number of subjects: 0
Study 34531443 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of monitoring radioactive iodine uptake
Number of subjects: 0
Study 34531537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily
Number of subjects: 30
Study 34531588 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR) T-cells
Number of subjects: 0
Study 34531755 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment, specific dosage and duration not available
Number of subjects: 0
Study 34531755 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34532363 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Number of subjects: 0
Study 34532363 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 34532768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transperineal laser ablation (TPLA)
Number of subjects: 44
Study 34532852 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic THC analogue (dronabinol, nabilone)
Number of subjects: 126
Study 34532852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoids (including natural delta-9-tetrahydrocannabinol)
Number of subjects: 126
Study 34532852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 126
Study 34532852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 34533416 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Inspiration Breath-Hold (DIBH)
Number of subjects: 10
Study 34533416 — intervention group
Group type: COMPARATOR
Intervention: Free Breathing (FB)
Number of subjects: 10
Study 34533464 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 70
Study 34533464 — intervention group
Group type: EXPERIMENTAL
Intervention: User acceptance testing
Number of subjects: 70
Study 34533472 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibodies measured in saliva
Number of subjects: 1850
Study 34533472 — intervention group
Group type: COMPARATOR
Intervention: Adult comparator group
Number of subjects: 1850
Study 34533472 — intervention group
Group type: COMPARATOR
Intervention: Adult validation group
Number of subjects: 1850
Study 34533644 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV-NAVA with NAVA levels progressively increased starting from 0.5 cmH2O
Number of subjects: 0
Study 34533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measures of socioeconomic status (SES)
Number of subjects: 0
Study 34533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective social class (SSC)
Number of subjects: 0
Study 34533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated conceptual socioecological model
Number of subjects: 0
Study 34533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical models connecting SES and SSC
Number of subjects: 0
Study 34533656 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical implications
Number of subjects: 0
Study 34533772 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PIF
Number of subjects: 1200
Study 34533772 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal PIF
Number of subjects: 1200
Study 34533772 — intervention group
Group type: EXPERIMENTAL
Intervention: No inhalation technique errors
Number of subjects: 1200
Study 34533772 — intervention group
Group type: COMPARATOR
Intervention: Inhalation technique errors
Number of subjects: 1200
Study 34533772 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhering to medication
Number of subjects: 1200
Study 34533772 — intervention group
Group type: COMPARATOR
Intervention: Not adhering to medication
Number of subjects: 1200
Study 34533772 — intervention group
Group type: EXPERIMENTAL
Intervention: PIF measurements, inhalation technique, medication adherence
Number of subjects: 1200
Study 34534134 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI threshold for arm circumference ≤26 cm
Number of subjects: 11585
Study 34534134 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI threshold for arm circumference ≤34 cm
Number of subjects: 11585
Study 34534134 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI threshold for arm circumference ≤44 cm
Number of subjects: 11585
Study 34534134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of BMI for predicting arm circumference
Number of subjects: 11585
Study 34534157 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid amplification
Number of subjects: 42
Study 34534180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic migraine (CM)
Number of subjects: 150
Study 34534180 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic migraine (EM)
Number of subjects: 150
Study 34534180 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study 34534180 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients with migraine
Number of subjects: 150
Study 34534188 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Health Intervention (DHI) consisting of a smartphone application, smartwatch, and wireless blood pressure monitor, costing $2750 per patient.
Number of subjects: 0
Study 34534188 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone.
Number of subjects: 0
Study 34534199 — intervention group
Group type: EXPERIMENTAL
Intervention: OAB-V8 Questionnaire
Number of subjects: 124
Study 34534223 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-RNA detection in blood
Number of subjects: 97
Study 34534223 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-RNA detection in CSF
Number of subjects: 97
Study 34534223 — intervention group
Group type: COMPARATOR
Intervention: Combined trypanosome detection in lymph and blood
Number of subjects: 97
Study 34534280 — intervention group
Group type: EXPERIMENTAL
Intervention: α-ketoglutaric acid elevation at day + 100 (D100) and at the onset of cGVHD
Number of subjects: 222
Study 34534280 — intervention group
Group type: COMPARATOR
Intervention: Metabolomic patterns at D100
Number of subjects: 222
Study 34534280 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic correlation patterns with clinical presentation
Number of subjects: 222
Study 34534280 — intervention group
Group type: EXPERIMENTAL
Intervention: α-ketoglutaric acid as a metabolomic biomarker
Number of subjects: 222
Study 34534337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided high-intensity focused ultrasound neurotomy
Number of subjects: 10
Study 34534421 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Antipsychotic Medication plus Customized Adherence Enhancement
Number of subjects: 0
Study 34534421 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34534430 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (6.4 mg per kilogram of body weight)
Number of subjects: 91
Study 34534514 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib, venetoclax, and obinutuzumab
Number of subjects: 37
Study 34534722 — intervention group
Group type: EXPERIMENTAL
Intervention: A fumigatus sensitization (positive skin prick test or specific IgE)
Number of subjects: 318
Study 34534722 — intervention group
Group type: COMPARATOR
Intervention: A fumigatus nonsensitized subjects
Number of subjects: 318
Study 34535102 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdental papilla biopsy protocol
Number of subjects: 148
Study 34535275 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes to departmental strategies for airway management
Number of subjects: 3786
Study 34535360 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial insulin therapy for ≥3 months
Number of subjects: 1194
Study 34535360 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline HbA1c (>8%)
Number of subjects: 1194
Study 34535360 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller difference between baseline and target HbA1c levels
Number of subjects: 1194
Study 34535471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative skeletal muscle tissue oxygenation (SmO2)
Number of subjects: 70
Study 34535471 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hsTnT) measured preoperatively and on the first and second day after surgery
Number of subjects: 70
Study 34535471 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal cerebral tissue oxygenation
Number of subjects: 70
Study 34535471 — intervention group
Group type: EXPERIMENTAL
Intervention: MINS and ICU admission within 30 days
Number of subjects: 70
Study 34535487 — intervention group
Group type: EXPERIMENTAL
Intervention: General Practitioner (GP)
Number of subjects: 452
Study 34535487 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist (PT)
Number of subjects: 452
Study 34535487 — intervention group
Group type: COMPARATOR
Intervention: Chiropractor (C)
Number of subjects: 452
Study 34535796 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-positive patients during the pandemic
Number of subjects: 5307
Study 34535796 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-negative patients during the pandemic
Number of subjects: 5307
Study 34535796 — intervention group
Group type: COMPARATOR
Intervention: COVID-19-negative patients prepandemic
Number of subjects: 5307
Study 34536305 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study 34536405 — intervention group
Group type: EXPERIMENTAL
Intervention: Onasemnogene abeparvovec gene therapy (1·1×10^14 vg/kg) administered as a one-time intravenous infusion.
Number of subjects: 33
Study 34536405 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients in the PNCR cohort).
Number of subjects: 33
Study 34536990 — intervention group
Group type: EXPERIMENTAL
Intervention: sVHD (significant valvular heart disease)
Number of subjects: 983
Study 34537845 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 120
Study 34538132 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34538257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg every 2 weeks or every 4 weeks)
Number of subjects: 341
Study 34538260 — intervention group
Group type: EXPERIMENTAL
Intervention: SPG5 patients
Number of subjects: 17
Study 34538260 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 17
Study 34538260 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of SCA on T9
Number of subjects: 17
Study 34538263 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (37 participants)
Number of subjects: 72
Study 34538263 — intervention group
Group type: COMPARATOR
Intervention: Placebo (35 participants)
Number of subjects: 72
Study 34538625 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic phenotypes identified using the e'VM algorithm
Number of subjects: 827
Study 34538630 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA with CT-MPI
Number of subjects: 132
Study 34538630 — intervention group
Group type: COMPARATOR
Intervention: Coronary CTA alone
Number of subjects: 132
Study 34538630 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute MBF
Number of subjects: 132
Study 34538630 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative MBF
Number of subjects: 132
Study 34539356 — intervention group
Group type: EXPERIMENTAL
Intervention: CT38s at an infusion rate of 0.03 μg/kg/h
Number of subjects: 0
Study 34539429 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon training characteristics and anthropometric measurements
Number of subjects: 45
Study 34539429 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological determinants
Number of subjects: 45
Study 34539455 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Game requiring Emotional Regulation
Number of subjects: 0
Study 34539455 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34539521 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness intervention
Number of subjects: 114
Study 34539521 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 114
Study 34539546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplaque enhancement
Number of subjects: 0
Study 34539750 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL16 T123V181 haplotype
Number of subjects: 1620
Study 34539759 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34539777 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased degree values in the left thalamus
Number of subjects: 78
Study 34539777 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased degree values in the left cerebellum Crus I
Number of subjects: 78
Study 34539777 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased degree values in the left dorsolateral prefrontal cortex
Number of subjects: 78
Study 34539777 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased degree values in the right precuneus
Number of subjects: 78
Study 34539777 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased degree values in the left postcentral gyrus
Number of subjects: 78
Study 34539777 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM classification analysis
Number of subjects: 78
Study 34539777 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered degree values within and outside the CSTC circuit
Number of subjects: 78
Study 34540013 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy plus apatinib (250 mg/day for 28 days)
Number of subjects: 30
Study 34540651 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated genomic characterization by the Cancer Genome Atlas (TCGA) defining four distinct endometrial cancer subgroups (POLE mutated, microsatellite instability, low copy number, and high copy number)
Number of subjects: 0
Study 34540651 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of molecular alterations into established clinicopathologic risk factors
Number of subjects: 0
Study 34540651 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular profiling for tailoring adjuvant therapy in the high-intermediate-risk group
Number of subjects: 0
Study 34540696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chidamide, decitabine, cytarabine, idarubicin, and granulocyte-colony stimulating factor (CDIAG regimen)
Number of subjects: 35
Study 34540697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose apatinib combined with S-1
Number of subjects: 30
Study 34540703 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose craniospinal irradiation (18 Gy)
Number of subjects: 28
Study 34540877 — intervention group
Group type: EXPERIMENTAL
Intervention: N247 nutraceutical formula
Number of subjects: 250
Study 34540877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 34540919 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin for primary prevention of cardiovascular disease
Number of subjects: 0
Study 34541016 — intervention group
Group type: EXPERIMENTAL
Intervention: BTB autograft
Number of subjects: 646
Study 34541016 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue autograft
Number of subjects: 646
Study 34541016 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 646
Study 34541016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medial and lateral meniscal repairs
Number of subjects: 646
Study 34541016 — intervention group
Group type: COMPARATOR
Intervention: Isolated medial meniscal repairs
Number of subjects: 646
Study 34541016 — intervention group
Group type: COMPARATOR
Intervention: Isolated lateral meniscal repairs
Number of subjects: 646
Study 34541016 — intervention group
Group type: COMPARATOR
Intervention: Graft type
Number of subjects: 646
Study 34541429 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery or medical treatments for diverticular disease
Number of subjects: 0
Study 34541429 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatments, interventional radiology, and surgery
Number of subjects: 0
Study 34541886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic edema on MRI
Number of subjects: 161
Study 34541886 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings of hemorrhage
Number of subjects: 161
Study 34541886 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC values
Number of subjects: 161
Study 34541899 — intervention group
Group type: EXPERIMENTAL
Intervention: Rho GTPase signaling
Number of subjects: 0
Study 34542347 — intervention group
Group type: EXPERIMENTAL
Intervention: AAC Plus
Number of subjects: 0
Study 34542729 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial stiffness measures (pulse wave velocity, augmentation index) and HRV indices
Number of subjects: 304
Study 34542729 — intervention group
Group type: COMPARATOR
Intervention: HRV measure (parasympathetic function)
Number of subjects: 304
Study 34542729 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 304
Study 34542729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c
Number of subjects: 304
Study 34542729 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial distensibility
Number of subjects: 304
Study 34542871 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa animal component-free
Number of subjects: 167
Study 34543230 — intervention group
Group type: EXPERIMENTAL
Intervention: StayWell SMS text messaging intervention
Number of subjects: 193
Study 34543383 — intervention group
Group type: EXPERIMENTAL
Intervention: Uproleselan (10 mg/kg twice daily) plus MEC (mitoxantrone, etoposide, and cytarabine)
Number of subjects: 66
Study 34543383 — intervention group
Group type: EXPERIMENTAL
Intervention: Uproleselan (10 mg/kg twice daily) plus cytarabine and idarubicin (7 + 3)
Number of subjects: 66
Study 34543383 — intervention group
Group type: EXPERIMENTAL
Intervention: Uproleselan added to chemotherapy
Number of subjects: 66
Study 34543383 — intervention group
Group type: EXPERIMENTAL
Intervention: E-selectin expression >10% in R/R cohort
Number of subjects: 66
Study 34543477 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks (35 cycles)
Number of subjects: 40
Study 34543477 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (platinum-based, four to six cycles)
Number of subjects: 40
Study 34543477 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 40
Study 34543477 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 40
Study 34543753 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative negative polymerase chain reaction test for COVID-19
Number of subjects: 111
Study 34543759 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive HCWs
Number of subjects: 44698
Study 34543759 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive HCWs from dedicated COVID-19 wards
Number of subjects: 44698
Study 34543759 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontline HCWs
Number of subjects: 44698
Study 34543759 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive HCWs after 4-6 months
Number of subjects: 44698
Study 34543759 — intervention group
Group type: COMPARATOR
Intervention: Seroreverted participants
Number of subjects: 44698
Study 34544034 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital handheld hydrogen breath monitor (GIMate)
Number of subjects: 31
Study 34544034 — intervention group
Group type: COMPARATOR
Intervention: FDA-cleared device (H2 Check)
Number of subjects: 31
Study 34544050 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial ENDS devices
Number of subjects: 0
Study 34544050 — intervention group
Group type: COMPARATOR
Intervention: Non-menthol and menthol cigarettes
Number of subjects: 0
Study 34544269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual compartment suppositories
Number of subjects: 16
Study 34544430 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal challenge (50 g fat)
Number of subjects: 35
Study 34544675 — intervention group
Group type: EXPERIMENTAL
Intervention: COPPS risk predictors assessment at baseline
Number of subjects: 177
Study 34544675 — intervention group
Group type: EXPERIMENTAL
Intervention: COPPS
Number of subjects: 177
Study 34544679 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot intervention for stress, sleep, and feeding
Number of subjects: 45
Study 34544679 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot intervention for stress
Number of subjects: 45
Study 34544679 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot intervention for feeding
Number of subjects: 45
Study 34544679 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot intervention for sleep
Number of subjects: 45
Study 34545357 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 100
Study 34545357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34545967 — intervention group
Group type: EXPERIMENTAL
Intervention: Major hepatectomy (MHx)
Number of subjects: 0
Study 34546172 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative surveys and telephone interviews conducted in 2021, with follow-ups in 2022 and 2023.
Number of subjects: 2800
Study 34546172 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete choice experiment with a subsample of participants.
Number of subjects: 2800